Prevalence of chronic kidney disease in patients with chronic hepatitis B: A cross-sectional survey

2017 ◽  
Vol 24 (11) ◽  
pp. 1043-1051 ◽  
Author(s):  
L. Ning ◽  
W. Lin ◽  
X. Hu ◽  
R. Fan ◽  
X. Liang ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Chronic Hepatitis ◽  
Kidney Disease ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Cross Sectional Survey ◽  
Cross Sectional

Higher Resource Utilization and Healthcare Costs in Treated Chronic Hepatitis B Patients with Chronic Kidney Disease

2017 ◽  
Vol 152 (5) ◽  
pp. S1087
Author(s):  
Mindie H. Nguyen ◽  
Joseph K. Lim ◽  
Iris Liou ◽  
Jeremy Fraysse ◽  
Nicole Meyer ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Chronic Hepatitis ◽  
Kidney Disease ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Resource Utilization ◽  
Healthcare Costs

Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment

2018 ◽  
Vol 48 (9) ◽  
pp. 984-992 ◽  
Author(s):  
Grace Lai-Hung Wong ◽  
Henry Lik-Yuen Chan ◽  
Yee-Kit Tse ◽  
Terry Cheuk-Fung Yip ◽  
Kelvin Long-Yan Lam ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Chronic Hepatitis ◽  
Kidney Disease ◽  
Hepatitis B ◽  
Disease Progression ◽  
Chronic Hepatitis B ◽  
Chronic Kidney Disease Progression ◽  
Kidney Disease Progression

scholarly journals Chronic hepatitis B in a woman with chronic kidney disease

2020 ◽  
Vol 4 (11) ◽  
pp. 710-713
Author(s):  
Kh.G. Omarova ◽  
◽  
V.V. Makashova ◽  
◽  
Keyword(s):  
Chronic Kidney Disease ◽  
Chronic Hepatitis ◽  
Kidney Disease ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Antiviral Treatment ◽  
Chronic Kidney Disease Stage ◽  
Disease Stage ◽  
Renal Hypoplasia ◽  
One Year

A 38-year-old woman was diagnosed with phase 2 chronic hepatitis B without delta-agent (HBeAg+) with a high biochemical and viral load and significant liver fibrosis (F2) five years after renal allotransplantation for a chronic kidney disease stage 5 resulting from a congenital urogenital abnormality (left renal hypoplasia). This woman was switched from lamivudine, the first-generation nucleoside analogue, that she received for 6 years, to entecavir (after a 4-year interval). However, the development of the resistance to entecavir forced to switch to tenofovir. A positive virological response was achieved as demonstrated by the lack of the isolation of hepatitis B virus (HBV) DNA one year after starting treatment. Yet, HBV is not detected. In addition, F2 fibrosis down-graded to F0 by the METAVIR score (as demonstrated by liver fibroelastometry). The woman is currently being followed-up. KEYWORDS: chronic hepatitis B, chronic kidney disease, renal allotransplantation, antiviral treatment, nucleoside analogues. FOR CITATION: Omarova Kh.G., Makashova V.V. Chronic hepatitis B in a woman with chronic kidney disease. Russian Medical Inquiry. 2020;4(11):710–713. DOI: 10.32364/2587-6821-2020-4-11-710-713.

scholarly journals Chronic Kidney Disease amongst Patients with Chronic Hepatitis B Virus in a Low Income Country Setting

2019 ◽  
Vol 9 (2) ◽  
Author(s):  
Halle Marie Patrice ◽  
Eloumou Bagnaka Servais Albert ◽  
Nda Mefo’o Jean Pierre ◽  
Kanouo Yolande ◽  
Djantio Hilaire ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Kidney Disease ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Low Income ◽  
Low Income Country ◽  
Chronic Hepatitis B Virus ◽  
B Virus

How can we improve hepatitis B testing and management in primary care? A cross-sectional survey of GPs in England, 2015–2017

2018 ◽  
Vol 68 (suppl 1) ◽  
pp. bjgp18X697241
Author(s):  
Z Amin ◽  
K Beebeejaun ◽  
L Letley ◽  
B Mahange ◽  
K Harrington ◽  
...  
Keyword(s):  
Primary Care ◽  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Hepatitis B Surface Antigen ◽  
Treatment Options ◽  
Hbv Infection ◽  
Contact Tracing ◽  
Cross Sectional Survey ◽  
Cross Sectional

BackgroundChronic hepatitis B (HBV) infection can lead to life-threatening liver disease. In the UK, approximately 180,000 people are carriers. The disease is underdiagnosed and undertreated.AimAs part of a nurse-led intervention aimed at improving HBV contact-tracing and management, we ascertained GPs’ understanding of HBV and their perceived barriers and enablers to HBV diagnosis.MethodIn 2015, we asked 1324 GPs across 2 England regions about HBV-related knowledge and practice, using a questionnaire. We reported the proportion of GPs answering each question, with 95% confidence intervals (95% CI).Results254 GPs (18%) replied. Of those, 189(74%, 95%CI 68–79%) correctly identified hepatitis B surface antigen as a marker of current HBV infection, and 154 (61%, 95% CI = 54 to 66%) recognised IgM anti-HBc as a marker for differentiating acute from chronic cases. 219 GPs (86%, 95% CI = 81 to 90%) believed HBV knowledge among patients to be one of the main enablers to improved testing uptake and 208 (82%, 95% CI = 77 to 86%) identified lack of HBV knowledge among patients as a barrier to testing. Of all GP responders, 227 (89%, 95% CI = 85 to 93%) reported HBV training and education would be beneficial, and 185 (73%, 95% CI = 67 to 78%) reported knowledge of treatment options as a knowledge gap.ConclusionGPs perceive gaps in knowledge among patients and healthcare professionals as a factor potentially contributing to the under-ascertainment of chronic hepatitis B in England. Improving HBV awareness and knowledge among patients, their contacts, and increasing HBV-focused training for GPs, particularly in the interpretation of laboratory results and the treatment options, can improve case ascertainment and chronic HBV management in primary care.

Sign in / Sign up

Export Citation Format

Share Document